Goldman Sachs’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-55,300
| Closed | -$5.33M | – | 5573 |
|
|
2023
Q4 | $5.33M | Buy |
+55,300
| New | +$4.89M | ﹤0.01% | 3100 |
|
|
2022
Q4 | – | Sell |
-29,900
| Closed | -$2.54M | – | 5985 |
|
|
2022
Q3 | $2.54M | Buy |
+29,900
| New | +$2.66M | ﹤0.01% | 3765 |
|
|
2021
Q1 | – | Sell |
-50,200
| Closed | -$4.4M | – | 6089 |
|
|
2020
Q4 | $4.4M | Sell |
50,200
-4,800
| -9% | -$381K | ﹤0.01% | 3098 |
|
|
2020
Q3 | $4.18M | Buy |
55,000
+52,500
| +2,100% | +$5.31M | ﹤0.01% | 3043 |
|
|
2020
Q2 | $308K | Sell |
2,500
-55,000
| -96% | -$5.47M | ﹤0.01% | 4616 |
|
|
2020
Q1 | $4.86M | Sell |
57,500
-38,200
| -40% | -$3.29M | ﹤0.01% | 2670 |
|
|
2019
Q4 | $8.09M | Buy |
95,700
+60,000
| +168% | +$4.53M | ﹤0.01% | 2589 |
|
|
2019
Q3 | $2.41M | Buy |
35,700
+33,200
| +1,328% | +$2.56M | ﹤0.01% | 3413 |
|
|
2019
Q2 | $214K | Buy |
+2,500
| New | +$214K | ﹤0.01% | 4761 |
|
|
2018
Q2 | – | Sell |
-30,000
| Closed | -$2.43M | – | 5661 |
|
|
2018
Q1 | $2.43M | Buy |
+30,000
| New | +$2.57M | ﹤0.01% | 3460 |
|
|
2017
Q4 | – | Sell |
-16,800
| Closed | -$1.56M | – | 6353 |
|
|
2017
Q3 | $1.56M | Buy |
+16,800
| New | +$1.48M | ﹤0.01% | 4189 |
|
|
2017
Q1 | – | Sell |
-38,900
| Closed | -$3.22M | – | 6760 |
|
|
2016
Q4 | $3.22M | Hold |
38,900
| – | – | ﹤0.01% | 3427 |
|
|
2016
Q3 | $3.6M | Sell |
38,900
-73,100
| -65% | -$6.88M | ﹤0.01% | 3329 |
|
|
2016
Q2 | $8.71M | Buy |
112,000
+13,500
| +14% | +$1.15M | ﹤0.01% | 2417 |
|
|
2016
Q1 | $8.12M | Sell |
98,500
-286,300
| -74% | -$23.3M | ﹤0.01% | 2377 |
|
|
2015
Q4 | $40.3M | Buy |
384,800
+184,500
| +92% | +$19.3M | 0.01% | 1281 |
|
|
2015
Q3 | $21.1M | Buy |
200,300
+48,400
| +32% | +$6.47M | 0.01% | 1672 |
|
|
2015
Q2 | $20.8M | Sell |
151,900
-3,200
| -2% | -$397K | 0.01% | 1763 |
|
|
2015
Q1 | $19.3M | Buy |
155,100
+63,100
| +69% | +$6.69M | 0.01% | 1783 |
|
|
2014
Q4 | $8.32M | Buy |
+92,000
| New | +$7.65M | ﹤0.01% | 2509 |
|
|
2014
Q2 | – | Sell |
-40,000
| Closed | -$2.73M | – | 6975 |
|
|
2014
Q1 | $2.73M | Sell |
40,000
-20,000
| -33% | -$1.47M | ﹤0.01% | 3666 |
|
|
2013
Q4 | $4.22M | Buy |
60,000
+56,800
| +1,775% | +$3.86M | ﹤0.01% | 3266 |
|
|
2013
Q3 | $231K | Sell |
3,200
-94,100
| -97% | -$6.25M | ﹤0.01% | 5746 |
|
|
2013
Q2 | $5.42M | Buy |
+97,300
| New | +$6.06M | ﹤0.01% | 2647 |
|
Other funds holding BMRN
VCM
VPM
Goldman Sachs's BMRN Position: Q1 2026 in Review
Goldman Sachs reduced its BioMarin Pharmaceuticals (BMRN) stake by 17% in Q1 2026, selling an estimated $4.39M and leaving 379,596 shares worth $21.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2371.
Goldman Sachs first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $262M in Q1 2018. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Goldman Sachs held 379,596 shares of BioMarin Pharmaceuticals worth $21.4M as of Q1 2026.
- Goldman Sachs sold 75,316 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $4.39M.
- BioMarin Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2371 holding.
- Goldman Sachs first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's BioMarin Pharmaceuticals position peaked at $262M in Q1 2018.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.